Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53967#.VN2pzyzQrzE Author(s) Aaron J. Smith , John Oertle , Dino Prato * Affiliation(s) Envita, Scottsdale, USA . ABSTRACT Complex and late stage cancer patients are in need of novel methods of selecting and administering chemotherapy particularly for those patients who are refractory to current treatment methods. The use of biomarkers to enhance decision making with regard to the molecular profile of a person’s cancer is becoming more important in the practice of oncology. The standard for the last several decades is to elect chemotherapeutic agents based on staging and histological identification of the primary cancer site alone versus utilizing the genetic and molecular profile information along with histological primary cancer site and staging to select chemotherapy regimens. Cancers are caused by mutations that occur within cells and th...
Scientific Research Publishing